Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG777 in Moderate-to-severe Atopic Dermatitis
NCT06395948Phase 2Active, not recruiting
- Sponsor
- Apogee Therapeutics
- Start
- Apr 2024
- Primary completion
- Nov 2026
- Modality
- IgG Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of apg777 in atopic dermatitis (AD), sponsored by Apogee Therapeutics. Started Apr 2024; status: active, not recruiting.
02
Drugs
apg777
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06395948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395948.